The aim of the current study is to compare the effects of two corticosteroids, prednisolone acetate 1% (PA) and loteprednol etabonate 0.5% (LE), for the treatment of benzalkonium chloride (BAC)-induced dry eye syndrome (DES) in rats.
Methods:
DES was established by topical administration of 0.2% BAC, a commonly used preservative in ophthalmic drugs, for 1 week. Rats were divided into 3 groups just after establishment of DES: PA-treated (Group 1, n=10), LE-treated (Group 2, n=10), and vehicle-treated (Group 3, n=10). Rats were treated by topical administration of PA, LE, or vehicle twice daily for 1 week. The Schirmer test, break-up time score, Fluorescein staining, Rose Bengal staining, and inflammatory index scoring (IIS) tests were performed at all weeks. After the end of the study, eyes of the rats were enucleated and analyzed using light microscopy.
Results:
The mean aqueous tear volume was significantly increased in both PA- and LE-treated rats (P<0.05), although decreased in vehicle-treated rats (P>0.05). Histologically, diffuse inflammatory cell infiltration was observed in vehicle-treated rats, while inflammation induced by BAC was almost completely resolved in both PA- and LE-treated groups.
Conclusions:
In the current study, we showed that both PA and LE are effective treatments in a rat model of BAC-induced DES, which is commonly observed in clinics. No significant differences were observed between the 2 corticosteroids in the efficacy of BAC-induced type of DES treatment.
Get full access to this article
View all access options for this article.
References
1.
International Dry Eye WorkShop. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop. Ocul. Surf., 5:75–92, 2007.
2.
PflugfelderS.C.Prevalence, burden, and pharmacoeconomics of dry eye disease review. Am. J. Manag. Care., 14:102–106, 2008.
3.
NicholsK.K., FoulksG.N., BronA.J., et al.The international workshop on meibomiangland dysfunction-executive summary. Invest. Ophthalmol. Vis. Sci., 30:1922–1929, 2011.
4.
PflugfelderS.C.Anti-inflammatory therapy of dry eye. Ocul. Surf., 1:31–36, 2003.
5.
International Dry Eye WorkShop. Management and therapy of dry eye disease: report of the management and therapy subcommittee of the international dry eye workShop. Ocul. Surf., 5:163–178, 2007.
6.
NaK.S., MokJ.W., KimJ.Y., et al.Correlations between tearcytokines, chemokines, and soluble receptors and clinical severity of dry eye disease. Invest. Ophthalmol. Vis. Sci., 13:5443–5450, 2012.
7.
AlhatemA., CavalcantiB., and HamrahP.In vivo confocal microscopy in dry eye disease and related conditions. Semin. Ophthalmol., 27:138–148, 2012.
8.
ChenW., ZhangX., ZhangJ., et al.A murine model of dry eye induced by an intelligently controlled environmental system. Invest. Ophthalmol. Vis. Sci., 49:1386–1391, 2008.
9.
LinZ., LiuX., ZhouT., et al.A mouse dry eye model induced by topical administration of benzalkonium chloride. Mol. Vis., 25:257–264, 2011.
10.
XiongC., ChenD., LiuJ., et al.A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride. Invest. Ophthalmol. Vis. Sci., 49:1850–1856, 2008.
11.
ZhuL., ZhangC., and ChuckR.S.Topicalsteroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model. Mol. Vis., 18:1803–1812, 2012.
12.
PaivaC.S., and PflugfelderS.C.Rationale for anti-inflammatory therapy in dry eye syndrome. Arq. Bras. Oftalmol., 71:89–95, 2008.
13.
LekhanontK., LeyngoldI.M., Suwan-ApichonO., et al.Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model. Cornea., 26:84–89, 2007.
14.
MarshP., and PflugfelderS.C.Topical non-preserved methylprednisolone therapy of keratoconjunctivitis siccain Sjogren's syndrome. Ophthalmology., 106:811–816, 1999.
15.
Sainz D.L.M.S.M., SimónC.C., and KabbaniO.Nonpreserved topical steroids and lacrimal punctal occlusion for severe keratoconjunctivitis sicca. Arch. Soc. Esp. Oftalmol., 75:751–756, 2000.
16.
PflugfelderS.C, MaskinS.L., AndersonB., ChodoshJ., et al.A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am. J. Ophthalmol., 138:444–457, 2004.
17.
De PaivaC.S., CorralesR.M., VillarrealA.L., et al.Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp. Eye Res., 83:526–535, 2006.
18.
PaulyA., BrignoleB.F., LabbeA., et al.New tools for the evaluation of toxic ocular surface changes in the rat. Invest. Ophthalmol. Vis. Sci., 48:5473–5483, 2007.
19.
Van BijsterveldO.P.Diagnostic test in the Sicca sydrome. Arc. Ophthalmol., 2:10–14, 1999.
20.
LariaC., AlioJ.L., and RuizM.J.M.Combined non-steroidal therapy in experimental corneal injury. Ophthalmic. Res., 29:145–153, 1997.
21.
LempM.A.Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J., 21:222–232., 1995.
22.
McCabeE., and NarayananS.Advancements in anti-inflammatory therapy for dry eye syndrome. Optometry. 80:555–566, 2009.
23.
BartlettJ.D., HorwitzB., LaibovitzR., et al.Intraocular pressure response to loteprednol etabonate in known steroid responders. J. Ocul. Pharmacol., 9:157–165, 1993.
24.
BaudouinC.The pathology of dry eye. Surv. Ophthalmol., 45:211–220, 2001.
25.
OzcuraF., DundarS.A., MeteogluI., et al.Effects of long-term passive smoking on vascular endothelial growth factor and apoptosis markers expression in lens and corneal epithelial cells: an experimental study. Turk. J. Med. Sci., 39:843–848, 2009.
26.
PflugfelderS.C.Antiinflammatory therapy for dry eye. Am. J. Ophthalmol., 137:337–342, 2004.
27.
YavuzB., BozdagP.S., and UnluN.An overview on dry eye treatment: approaches for cyclosporin a delivery. Sci.World J., 2012:194848, 2012.
28.
NagelhoutT.J., GamacheD.A., RobertsL., et al.Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye. J. Ocul. Pharmacol. Ther., 21:139–148, 2005.
29.
AvundukA.M., AvundukM.C., VarnellE.D., et al.The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am. J. Ophthalmol., 136:593–602, 2003.
30.
De PaivaC.S., CorralesR.M., VillarrealA.L., et al.Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. Invest. Ophthalmol. Vis. Sci., 47:2847–2856, 2006.
31.
FoulksG.N.The evolving treatment of dry eye. Ophthalmol. Clin. North Am., 16:29–35, 2003.
32.
ComstockT.L., and DecoryH.H.Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int. J. Inflam., 2012:789623, 2012.
33.
MohamedA.B., and MohamedI.K.Topical corticosteroid drops in the management of dry eye. Egypt. J. Hosp. Med., 39:181–188, 2010.
34.
GlogowskiS., and ProkschJ.Ocular pharmacokinetics of loteprednol etabonate following ocular administration of a novel ointment formulation or a suspension (Lotemax®) in rabbits with corneal inflammation. Proceedings of the Association for Research in Vision and Ophthalmology MeetingFt. Lauderdale, FL, USA, 2010.
35.
DruzgalaP., WuW.M., and BodorN.Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr. Eye Res., 10:933–937, 1991.
36.
LiC., SongY., LuanS., et al.Research on the stability of a rabbit dry eye model induced by topical application of the preservative benzalkonium chloride. PLoS One, 7:e33688, 2012.
37.
McGinnigleS., NarooS.A., and EperjesiF.Evaluation of dry eye. Surv. Ophthalmol., 57:293–316, 2012.
38.
BarabinoS., and DanaM.R.Animal models of dry eye: a critical assessment of opportunities and limitations. Invest. Ophthalmol. Vis. Sci., 45:1641–1646, 2004.
39.
Enríquez-de-SalamancaA., CastellanosE., SternM.E, et al. Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Mol. Vis., 16:862–873, 2010.
